Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia

被引:53
|
作者
Danis, Etienne [1 ]
Yamauchi, Taylor [1 ]
Echanique, Kristen [1 ]
Zhang, Xi [1 ]
Haladyna, Jessica N. [1 ]
Riedel, Simone S. [1 ]
Zhu, Nan [2 ]
Xie, Huafeng [3 ,4 ,5 ]
Orkin, Stuart H. [3 ,4 ,5 ]
Armstrong, Scott A. [6 ,7 ]
Bernt, Kathrin M. [1 ,8 ]
Neff, Tobias [1 ,8 ]
机构
[1] Univ Colorado Denver, Dept Pediat, Sect Pediat Hematol Oncol Bone Marrow Transplanta, Aurora, CO 80045 USA
[2] Blood Ctr Wisconsin, Blood Res Inst, Stem Cell Biol & Hematopoiesis Program, Milwaukee, WI 53226 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA 02115 USA
[5] HHMI, Boston, MA 02115 USA
[6] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Med, New York, NY 10065 USA
[7] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Pediat, New York, NY 10065 USA
[8] Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO 80045 USA
来源
CELL REPORTS | 2016年 / 14卷 / 08期
关键词
REPRESSIVE COMPLEX 2; ACUTE MYELOID-LEUKEMIA; METHYLTRANSFERASE GENE EZH2; MLL-REARRANGED LEUKEMIA; GROUP PROTEIN EZH2; SOMATIC MUTATIONS; G-CSF; DIFFERENTIATION; INHIBITION; TRANSFORMATION;
D O I
10.1016/j.celrep.2016.01.064
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive subtype of ALL distinguished by stem-cell-associated and myeloid transcriptional programs. Inactivating alterations of Poly-comb repressive complex 2 components are frequent in human ETP-ALL, but their functional role is largely undefined. We have studied the involvement of Ezh2 in a murine model of NRASQ61K-driven leukemia that recapitulates phenotypic and transcriptional features of ETP-ALL. Homozygous inactivation of Ezh2 cooperated with oncogenic NRASQ61K to accelerate leukemia onset. Inactivation of Ezh2 accentuated expression of genes highly expressed in human ETP-ALL and in normal murine early thymic progenitors. Moreover, we found that Ezh2 contributes to the silencing of stem-cell-and early-progenitor-cell-associated genes. Loss of Ezh2 also resulted in increased activation of STAT3 by tyrosine 705 phosphorylation. Our data mechanistically link Ezh2 inactivation to stem-cell-associated transcriptional programs and increased growth/survival signaling, features that convey an adverse prognosis in patients.
引用
收藏
页码:1953 / 1965
页数:13
相关论文
共 50 条
  • [1] EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia
    Schaefer, Vivien
    Ernst, Jana
    Rinke, Jenny
    Winkelmann, Nils
    Beck, James F.
    Hochhaus, Andreas
    Gruhn, Bernd
    Ernst, Thomas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (07) : 1641 - 1650
  • [2] Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia
    Rashkovan, Marissa
    Albero, Robert
    Gianni, Francesca
    Perez-Duran, Pablo
    Miller, Hannah, I
    Mackey, Adam L.
    Paietta, Elisabeth M.
    Tallman, Martin S.
    Rowe, Jacob M.
    Litzow, Mark R.
    Wiernik, Peter H.
    Luger, Selina
    Sulis, Maria Luisa
    Soni, Rajesh K.
    Ferrando, Adolfo A.
    CANCER DISCOVERY, 2022, 12 (03) : 856 - 871
  • [3] The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and Opportunities
    Bernt, Kathrin M.
    Hunger, Stephen P.
    Neff, Tobias
    FRONTIERS IN PEDIATRICS, 2016, 4
  • [4] Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick
    Tarantini, Francesco
    Cumbo, Cosimo
    Anelli, Luisa
    Zagaria, Antonella
    Specchia, Giorgina
    Musto, Pellegrino
    Albano, Francesco
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [5] Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
    Tremblay, Cedric S.
    Saw, Jesslyn
    Yan, Feng
    Boyle, Jacqueline A.
    Amarasinghe, Ovini
    Abdollahi, Shokoufeh
    Vo, Anh N. Q.
    Shields, Benjamin J.
    Mayoh, Chelsea
    Mccalmont, Hannah
    Evans, Kathryn
    Steiner, Anna
    Parsons, Kevin
    Mccormack, Matthew P.
    Powell, David R.
    Wong, Nicholas C.
    Jane, Stephen M.
    Lock, Richard B.
    Curtis, David J.
    LEUKEMIA, 2025, 39 (03) : 577 - 589
  • [6] Blast phase of chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia
    Shuyu, E.
    Xu, Jie
    Wang, Sa A.
    Tang, Guilin
    Jabbour, Elias J.
    Li, Shaoying
    You, M. James
    Medeiros, L. Jeffrey
    Yin, C. Cameron
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, : 231 - 239
  • [7] Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
    Summers, Ryan J.
    Jain, Juhi
    Vasileiadi, Eleana
    Smith, Brittany
    Chimenti, Madison L.
    Yeung, Tsz Y.
    Kelvin, James
    Wang, Xiaodong
    Frye, Stephen, V
    Earp, H. Shelton
    Tyner, Jeffrey W.
    Dreaden, Erik C.
    DeRyckere, Deborah
    Graham, Douglas K.
    CANCERS, 2022, 14 (24)
  • [8] Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review
    Zhao, Yihan
    Jiang, Shiqing
    Tang, Yujun
    Zhao, Lin
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (04) : 483 - 488
  • [9] Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen
    Zhang, Xiang
    Li, Jianhu
    Jin, Jie
    Yu, Wenjuan
    ANNALS OF HEMATOLOGY, 2020, 99 (02) : 395 - 397
  • [10] Optimized outcome prediction of oncogenetic mutations in non-early T-cell precursor acute lymphoblastic leukemia
    Peng, Li-Jun
    Wang, Si-Si
    Guo, Shan-Shan
    Zhang, Jiao-Jiao
    Liu, Yuan-Fang
    Rousseaux, Sophie
    Khochbin, Saadi
    Chen, Bing
    Wang, Jin
    Mi, Jian-Qing
    IMMUNOBIOLOGY, 2022, 227 (03)